Receptor Binding Domain Based HIV Vaccines.

　　Liu H, Bi W, Wang Q, Lu L, Jiang S.

     Biomed Res Int. 2015;2015:594109.

　　Abstract

　　This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding domain of gp120 as a target for developing AIDS vaccines. And we recommend some measures that could induce efficiently and produce cross-reactive neutralizing antibodies with high binding affinity. Those measures may offer a new way of the research and development of the potent and broad AIDS vaccines.

　　http://www.ncbi.nlm.nih.gov/pubmed/25670504